90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.
Proceedings of the National Academy of Sciences of the United States of America.
Times cited: 21
Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008).
Cancer Immunology Immunotherapy.
Times cited: 40